Brainsway (NASDAQ:BWAY) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Brainsway (NASDAQ:BWAY) from a hold rating to a buy rating in a research report report published on Saturday.

Other research analysts have also issued reports about the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Northland Securities set a $15.00 price target on shares of Brainsway in a research note on Thursday, January 22nd. Finally, HC Wainwright upped their price objective on shares of Brainsway from $12.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 26th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Brainsway Stock Performance

Shares of BWAY stock opened at $12.34 on Friday. Brainsway has a fifty-two week low of $3.92 and a fifty-two week high of $13.31. The stock has a 50 day simple moving average of $11.75 and a two-hundred day simple moving average of $9.34. The company has a market cap of $483.97 million, a P/E ratio of 82.27 and a beta of 1.20.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BWAY. Essex Investment Management Co. LLC increased its position in shares of Brainsway by 3.2% during the third quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock worth $4,682,000 after acquiring an additional 9,744 shares in the last quarter. ARK Investment Management LLC acquired a new position in Brainsway during the 4th quarter valued at about $2,422,000. Y.D. More Investments Ltd increased its holdings in Brainsway by 559.8% during the 4th quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after purchasing an additional 97,537 shares in the last quarter. Two Sigma Investments LP increased its holdings in Brainsway by 25.2% during the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after purchasing an additional 20,706 shares in the last quarter. Finally, Legato Capital Management LLC raised its stake in shares of Brainsway by 9.3% in the fourth quarter. Legato Capital Management LLC now owns 97,376 shares of the company’s stock worth $1,852,000 after purchasing an additional 8,295 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Brainsway

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Wall Street Zen upgraded Brainsway to a “Buy”, which can attract buyers and support upside sentiment. Read More.
• Neutral Sentiment: Reported short-interest figures show zero shares short (and an unchanged/strange read), so there is no clear short-pressure signal for the stock at the moment; this data appears unreliable and is unlikely to move the stock materially.
• Negative Sentiment: Northland Securities cut multiple near-term EPS estimates across FY2025–FY2026 (Q4’25, Q1–Q4’26 and FY2025), trimming full‑year FY2025 EPS to $0.09 from $0.17 and lowering several quarterly forecasts — a direct negative for near-term earnings expectations and analyst sentiment.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.